News Releases Keyword Search Year None2022202120202019201820172016 Mar-04-2021 Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update Feb-24-2021 Oncternal Therapeutics to Participate in March Investor Conferences Feb-22-2021 Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Jan-28-2021 Oncternal Therapeutics Announces the Appointment of Dr. Rosemary Mazanet to the Board of Directors Jan-14-2021 Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy Program Jan-07-2021 Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell Therapies Jan-05-2021 Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference Dec-14-2020 Oncternal Therapeutics Announces Closing of $86.2 Million Bought Deal and Full Exercise of Option to Purchase Additional Shares Dec-09-2020 Oncternal Therapeutics Increases Previously Announced Bought Deal to $75.0 Million Dec-09-2020 Oncternal Therapeutics Announces $40.0 Million Bought Deal Offering Pagination First page « first Previous page ‹ previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page next › Last page last »
